Santhosh Sisira, Malik Bilal, Kalantary Atefeh, Kunadi Arvind
Internal Medicine, Adichunchanagiri Institute of Medical Sciences, Rajiv Gandhi University of Health Sciences, B.G. Nagara, IND.
Internal Medicine, McLaren Health Care/Michigan State University (MSU), Flint, USA.
Cureus. 2022 Jul 5;14(7):e26582. doi: 10.7759/cureus.26582. eCollection 2022 Jul.
Immune thrombocytopenic purpura (ITP) has been linked to the COVID-19 vaccine series as a rare adverse event but has recently emerged in the literature as a sequela of natural COVID-19 infection. ITP is a diagnosis of exclusion where a diagnosis is made by having isolated thrombocytopenia (platelet count <100,000/μL) and no other identifiable etiology for the thrombocytopenia. We share the case of a young male without any history of hematological or immunological disorders presenting with severe, symptomatic thrombocytopenia following a natural COVID-19 infection. Patients should be made aware of the potential risk of adverse events with not only vaccination but also even mild cases of natural infection with COVID-19. An emphasis should be placed on the fact that the benefits of vaccination continue to outweigh the potential risks of adverse events, even in those with a pre-existing diagnosis of ITP.
免疫性血小板减少性紫癜（ITP）已被列为新冠疫苗系列罕见的不良事件，但最近在文献中作为自然感染新冠病毒后的后遗症出现。ITP是一种排除性诊断，即通过孤立性血小板减少（血小板计数<100,000/μL）且无其他可识别的血小板减少病因来做出诊断。我们分享一例年轻男性病例，该患者无血液学或免疫学疾病史，在自然感染新冠病毒后出现严重的、有症状的血小板减少。应让患者了解不仅接种疫苗，甚至新冠病毒轻度自然感染都存在不良事件的潜在风险。应强调的是，即使对于已有ITP诊断的患者，接种疫苗的益处仍大于不良事件的潜在风险。
